Description: Phase 1B/2, Open Label, Multicenter, Dose Escalation and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of PF-07220060 in Combination with PF-07104091 Plus Endocrine Therapy in participants with Advanced Solid Tumor
Target Patient Population: All solid tumors, but is especially attractive for HR+, HER2- breast cancer
Study Design: Drug is given orally twice daily.